rp 73401 has been researched along with roflumilast in 13 studies
| Studies (rp 73401) | Trials (rp 73401) | Recent Studies (post-2010) (rp 73401) | Studies (roflumilast) | Trials (roflumilast) | Recent Studies (post-2010) (roflumilast) |
|---|---|---|---|---|---|
| 92 | 0 | 23 | 566 | 90 | 425 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Artis, DR; Bollag, G; Card, GL; England, BP; Fong, D; Gillette, S; Ibrahim, PN; Kim, SH; Lee, B; Luu, C; Milburn, MV; Powell, B; Schlessinger, J; Suzuki, Y; Tabrizizad, M; Zhang, KY | 1 |
| Barlow, DJ; Ehrman, TM; Hylands, PJ | 1 |
| Anzola, JV; Beauregard, C; Chen, J; Coyle, AR; Gamache, DA; Govek, SP; Hellberg, MR; Hsien, JN; Lerch, JM; Liao, JC; Malecha, JW; Noble, SA; Oshiro, G; Shiau, AK; Staszewski, LM; Thomas, DJ; Yanni, JM | 1 |
| Ashton, TD; Bland, ND; Campbell, RK; Cotter, K; Fang, AP; Gangurde, R; Garceau, N; Gechijian, L; Gustafson, AE; McAllister, G; Ochiana, SO; Ondrechen, MJ; Ortenberg, R; Pollastri, MP; Tallman, C; Wang, C; Wang, Z | 1 |
| de Esch, IJ; de Graaf, C; Jansen, C; Kanev, GK; Kooistra, AJ; Leurs, R | 1 |
| He, J; Ke, H; Peng, T; Qi, B; Shi, J | 1 |
| Dai, YR; Xia, XD; Xu, ZJ | 1 |
| Beume, R; Bundschuh, DS; Marx, D; Wohlsen, A; Wollin, L | 1 |
| Husfeld, C; Ji, YH; Klein, U; Linnevers, C; McCluskie, K; Thomas, GR; Yang, A | 1 |
| Dunkern, T; Hatzelmann, A; Selige, J | 1 |
| Barg, M; Geerts, A; Quednau, R; Tersteegen, A; Wunder, F | 1 |
| Bailie, M; Chibucos, L; Christensen, PJ; Dils, AJ; Hazama, M; Horowitz, JC; Matsuo, T; Muraki, Y; Nikam, S; Sisson, TH; Subbotina, N; Tohyama, K | 1 |
| Abou Saleh, L; Aragon, IV; Boyd, A; Koloteva, A; McDonough, W; Murphy, JM; Rich, J; Richter, W | 1 |
2 review(s) available for rp 73401 and roflumilast
| Article | Year |
|---|---|
Advances in the Development of Phosphodiesterase-4 Inhibitors.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Development; Drug Discovery; Humans; Molecular Structure; Phosphodiesterase 4 Inhibitors; Protein Conformation; Quinolones; Vomiting | 2020 |
[Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Asthma; Benzamides; Bronchodilator Agents; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Lung Diseases; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyridines | 2004 |
11 other study(ies) available for rp 73401 and roflumilast
| Article | Year |
|---|---|
Structural basis for the activity of drugs that inhibit phosphodiesterases.
Topics: Binding Sites; Crystallography, X-Ray; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Protein Structure, Tertiary | 2004 |
In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.
Topics: Anti-Inflammatory Agents; Crystallography, X-Ray; Cyclooxygenase 1; Cyclooxygenase 2; Databases, Factual; Drug Design; Drugs, Chinese Herbal; Enzyme Inhibitors; JNK Mitogen-Activated Protein Kinases; Medicine, Chinese Traditional; Models, Chemical; Models, Molecular; Molecular Conformation; p38 Mitogen-Activated Protein Kinases; Phosphodiesterase 4 Inhibitors; Structure-Activity Relationship | 2010 |
Water-soluble PDE4 inhibitors for the treatment of dry eye.
Topics: 4-Aminopyridine; Animals; Anti-Inflammatory Agents; Binding Sites; Computer Simulation; Coumarins; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Dry Eye Syndromes; Phosphodiesterase 4 Inhibitors; Rabbits; Rats; Water | 2010 |
Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Benzamides; Catalytic Domain; Humans; Models, Molecular; Molecular Structure; Pyridines; Recombinant Proteins; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African | 2011 |
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
Topics: Databases, Protein; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Structure-Activity Relationship | 2016 |
Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Aminopyridines; Animals; Benzamides; Bronchial Spasm; Bronchoalveolar Lavage Fluid; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Models, Animal; Immunization; Male; Neutrophils; Nitriles; Ovalbumin; Phosphodiesterase Inhibitors; Pneumonia; Pyridines; Rats; Respiratory Hypersensitivity; Rolipram; Serotonin; Treatment Outcome; Tumor Necrosis Factor-alpha | 2006 |
Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Cytokines; Humans; Inflammation; Interleukin-8; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Phosphodiesterase Inhibitors; Pyridines | 2006 |
The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine-induced proliferation and myofibroblast conversion.
Topics: Aminopyridines; Benzamides; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Cytokines; Fibroblast Growth Factor 2; Fibroblasts; Gene Expression Profiling; Humans; Interleukin-1beta; Isoenzymes; Lung; Myofibroblasts; Phosphodiesterase 4 Inhibitors; Pulmonary Fibrosis; Pyridines; RNA, Small Interfering; Transfection; Transforming Growth Factor beta | 2011 |
Characterization of the cellular activity of PDE 4 inhibitors using two novel PDE 4 reporter cell lines.
Topics: Aminopyridines; Animals; Benzamides; CHO Cells; Cricetulus; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide-Gated Cation Channels; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Models, Biological; Nitriles; Phosphodiesterase 4 Inhibitors; Pyridines; Receptors, Adrenergic, beta-1; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury.
Topics: Alveolar Epithelial Cells; Aminopyridines; Animals; Benzamides; Cells, Cultured; Chemokines; Cyclic AMP; Cyclopropanes; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fibroblasts; Humans; Isoquinolines; Mice, Inbred C57BL; Mice, Transgenic; Phosphodiesterase 4 Inhibitors; Pulmonary Fibrosis; Pulmonary Surfactant-Associated Protein D; Pyridines; Tumor Necrosis Factor-alpha | 2018 |
PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.
Topics: Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Disease Models, Animal; Female; Gastroparesis; Mice; Mice, Nude; Phosphodiesterase 4 Inhibitors; Pyridines; Pyrimidinones; Rolipram | 2020 |